<table>
<tr><td>Technology/ Title</td><td colspan="3">DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy</td></tr>
<tr><td rowspan="2">Technology Type</td><td>☐Biotechnology</td><td colspan="2">☐Device/Diagnostics</td></tr>
<tr><td>☐Pharmaceutical</td><td colspan="2">☐Others:
Oncology/Cancer Immunotherapy</td></tr>
<tr><td rowspan="3">Contact Person</td><td colspan="2">Name: Hua-Hsuan Liang</td><td>Title: Acting Section Chief</td></tr>
<tr><td colspan="2">Telephone(work): 886-37-206166#33206</td><td>Mobile:</td></tr>
<tr><td colspan="3">Email: huahsuan@nhri.edu.tw</td></tr>
<tr><td>Link</td><td colspan="3">http://</td></tr>
<tr><td>Technology Description</td><td colspan="3">Introduction:
CD47-SIRP α “Do-not-eat- me” signaling axis is myeloid-specific innate immune checkpoint. Cancer cells express CD47 on the cell surface enable them to evade detection by the innate immune system and thus avoid destruction by macrophages.
Key Features of DBPR22998:
❖ An orally bioavailable small molecule isoQC inhibitor modulating CD47-SIRPa ”Do not eat me” cancer immune checkpoint activity
❖ Target post translational modification process of CD47 protein synthesis
❖ Demonstrate potent inhibitory activity of isoQC enzyme and effective blocking of CD47 and SIRPα interaction in CD47-expression cell lines in vitro
❖ Demonstrate antibody-dependent cellular phagocytosis (ADCP) in human monocyte-derived macrophage ex vivo culture
❖ Demonstrate anti-tumor efficacy in combination with antibody therapeutics in solid tumors and hematologic cancers
❖ Demonstrate more potent isoQC inhibitory activity in vitro and greater anti-tumor efficacy in vivo than those of the current clinical agent</td></tr>
</table>

	
Intellectual Property	US/PCT patents
Key Publications	NA
Business Opportunity	Technology transfer; Co-development